J.W. Cole Advisors Inc. reduced its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 55.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,503 shares of the exchange traded fund’s stock after selling 13,077 shares during the period. J.W. Cole Advisors Inc.’s holdings in SPDR S&P Biotech ETF were worth $1,225,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in XBI. Cibc World Market Inc. boosted its stake in shares of SPDR S&P Biotech ETF by 8.3% during the fourth quarter. Cibc World Market Inc. now owns 19,523 shares of the exchange traded fund’s stock valued at $2,380,000 after purchasing an additional 1,490 shares in the last quarter. Calton & Associates Inc. boosted its stake in shares of SPDR S&P Biotech ETF by 3.8% during the fourth quarter. Calton & Associates Inc. now owns 5,441 shares of the exchange traded fund’s stock valued at $663,000 after purchasing an additional 201 shares in the last quarter. One Capital Management LLC bought a new position in shares of SPDR S&P Biotech ETF during the fourth quarter valued at approximately $315,000. Thompson Siegel & Walmsley LLC boosted its stake in shares of SPDR S&P Biotech ETF by 2.6% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 8,000 shares of the exchange traded fund’s stock valued at $975,000 after purchasing an additional 200 shares in the last quarter. Finally, Ascension Capital Advisors Inc. bought a new position in shares of SPDR S&P Biotech ETF during the fourth quarter valued at approximately $1,117,000.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $131.38 on Wednesday. The firm’s 50 day moving average price is $132.23 and its 200-day moving average price is $126.86. SPDR S&P Biotech ETF has a 52-week low of $80.90 and a 52-week high of $139.19. The company has a market cap of $8.38 billion, a PE ratio of 11.47 and a beta of 0.85.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
